Cell-Type-Specific Repression of the Maspin Gene Is Disrupted Frequently by Demethylation at the Promoter Region in Gastric Intestinal Metaplasia and Cancer Cells

American Journal of Pathology

Volumn 163, Issue 5, 2003, Pages 1911-1919

  Akiyama, Yuji ^a   Maesawa, Chihaya ^a   Ogasawara, Satoshi ^a   Terashima, Masanori ^b   Masuda, Tomoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEMETHYLATING AGENT; MASPIN; MESSENGER RNA; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CANCER CELL; CELL SPECIFICITY; CELL TYPE; CLINICAL ARTICLE; DEMETHYLATION; GENE AMPLIFICATION; GENE DISRUPTION; GENE FREQUENCY; GENE OVEREXPRESSION; GENE SEQUENCE; HAPLOIDY; HUMAN; HUMAN CELL; HYPERMETHYLATION; HYPOMETHYLATION; IMMUNOREACTIVITY; INTESTINE METAPLASIA; ISOLATION PROCEDURE; MASPIN GENE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REPRESSOR GENE; RNA ANALYSIS; STOMACH CANCER; STOMACH EPITHELIUM; TUMOR SUPPRESSOR GENE;

EID: 0142182088     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63549-3     Document Type: Article

References (46)

1. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994, 263:526-529
2. Sheng S, Pemberton PA, Sager R: Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994, 269:30988-30993
3. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996, 93:11669-11674
4. Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB, Sager R: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 1998, 95:499-504
5. McGowen R, Biliran Jr H, Sager R, Sheng S: The surface of prostate carcinoma DU145 ceils mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 2000, 60:4771-4778
6. Biliran Jr H, Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 2001, 61:8676-8682
7. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, Zhang M: Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001, 61:6945-6951
8. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 2002, 100:452-455
9. Maass N, Hojo T, Rosel F, Ikeda T, Jonat W, Nagasaki K: Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem 2001, 34:303-307
10. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R, Kondo M, Jonas U, Kuczyk M: Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 2001, 95:337-342
11. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC: High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000, 19:2398-2403
12. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S: p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000, 275:6051-6054
13. Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med 2000, 6:196-199
14. Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W, Nagasaki K: Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001, 7:812-817
15. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002, 8:2924-2932
16. Son HJ, Sohn TS, Song SY, Lee JH, Rhee JC: Maspin expression in human gastric adenocarcinoma. Pathol Int 2002, 52:508-513
17. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE: Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002, 31:175-179
18. Costello JF, Vertino PM: Methylation matters: a new spin on maspin. Nat Genet 2002, 31:123-124
19. Domann FE, Rice JC, Hendrix MJ, Futscher BW: Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000, 85:805-810
20. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001, 61:2847-2851
21. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ: Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002, 102:623-628
22. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T: Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002, 161:399-403
23. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC: hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999, 59:159-164
24. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y, Imai K: Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer 1999, 83:309-313
25. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59:5438-5442
26. Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Yuasa Y: Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer 2000, 87:654-658
27. Shim YH, Kang GH, Ro JY: Correlation of p16 hypermethylat)on with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000, 80:689-695
28. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ: E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000, 92:569-573
29. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG: Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001, 61:7034-7038
30. Leung WK, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC, Sung JJ: Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001, 91:2294-2301
31. Nakamura S, Goto J, Kitayama M, Kino I: Application of the crypt-isolation technique to flow-cytometric analysis of DNA content in colorectal neoplasms. Gastroenterology 1994, 106:100-107
32. Nakamura S, Kino I, Baba S: Nuclear DNA content of isolated crypts of background colonic mucosa from patients with familial adenomatous polyposis and sporadic colorectal cancer. Gut 1993, 34:1240-1244
33. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22:2990-2997
34. Zhang M, Maass N, Magit D, Sager R: Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 1997, 8:179-186
35. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740
36. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994, 57:324-329
37. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol 1994, 144:511-517
38. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT: Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 1998, 78:971-973
39. Filipe MI, Osborn M, Linehan J, Sanidas E, Brito MJ, Jankowski J: Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer 1995, 71:30-36
40. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR: Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000, 156:537-543
41. Hamamoto T, Yokozaki H, Semba S, Yasui W, Yunotani S, Miyazaki K, Tahara E: Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J Clin Pathol 1997, 50:841-846
42. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK: Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000, 157:729-735
43. van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ: Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathoi 2002, 196:171-179
44. Zhang M, Magit D, Botteri F, Shi HY, He K, Li M, Furth P, Sager R: Maspin plays an important role in mammary gland development. Dev Biol 1999, 215:278-287
45. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, Hruban RH, Goggins M: Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002, 160:45-50
46. Cho M, Uemura H, Kim SC, Kawada Y, Yoshida K, Hirao Y, Konishi N, Saga S, Yoshikawa K: Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br J Cancer 2001, 85:563-567